CD53 and pachyonychia congenita: Systemic targeted radiation with RIT has therapeutic promise in advanced solid tumors, in particular for radiosensitive tumors such as PC with a selective and specific cell-surface antigen such as PSMA and an available antigen-specific, non-immunogenic mAb such as J591.